Asher Chanan-Khan

7PUBLICATIONS
91CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cardiovascular medicine and haematology not elsewhere classifiedMolecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 31, 2026
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Mazyar Shadman, Asher Chanan-Khan, David Campbell

|Jan 29, 2024
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.

Ricardo D Parrondo, Navnita Dutta, Betsy R LaPlant

|Jun 30, 2023
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.

John F Seymour, John C Byrd, Paolo Ghia

|Apr 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.

Sikander Ailawadhi, Zi Chen, Bo Huang

|Dec 19, 2022
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies.

Patrizia Mondello, Jonas Paludo, Joseph P Novak

|Sep 12, 2022
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance.

Matthew Ho, Saurabh Zanwar, Francis K Buadi

Pageof 2

Frequent Collaborators

4 joint publications

Sikander Ailawadhi

3 joint publications

Aneel Paulus

2 joint publications

Hengbang Wang

2 joint publications

Dajun Yang